SCHEMBL23219795

SCHEMBL23219795

CCNc1ccc(C(=O)N2CC(O)C2)nc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ VNN1 O95497 1/20 0.41
▸ TDP1 Q9NUW8 1/20 0.40
▸ ADRA2A P08913 2/20 0.39
▸ ADRA2B P18089 2/20 0.39
▸ ADRA2C P18825 2/20 0.39
▸ DHFR P00374 1/20 0.39
▸ PDE10A Q9Y233 1/20 0.37
▸ P4HTM Q9NXG6 1/20 0.37
▸ GABRA1 P14867 1/20 0.37
▸ PDE7A Q13946 1/20 0.37
▸ PLA2G1B P04054 1/20 0.36
▸ ATG4B Q9Y4P1 1/20 0.36
▸ TLR2 O60603 1/20 0.36
▸ TLR1 Q15399 1/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.36
▸ CSF1R P07333 1/20 0.36
▸ NAMPT P43490 1/20 0.35
▸ L3MBTL3 Q96JM7 1/20 0.35
▸ L3MBTL1 Q9Y468 1/20 0.35
▸ FLT3 P36888 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20940096 0.85 PDE10A (0.39) VNN1TDP1PDE10AGABRA1PDE7A
SCHEMBL23219796 0.82 TDP1 (0.41) VNN1TDP1PDE10AP4HTMGABRA1
SCHEMBL20940095 0.81 PDE10A (0.37) VNN1TDP1DHFRPDE10AGABRA1
SCHEMBL19766587 0.81 PLA2G1B (0.43) VNN1TDP1PDE10APDE7APLA2G1B
SCHEMBL13467096 0.77 PDE10A (0.56) VNN1TDP1PDE10AGABRA1TLR2
SCHEMBL30112058 0.75 P4HTM (0.60) TDP1ADRA2AADRA2BADRA2CP4HTM
SCHEMBL18405340 0.75 P4HTM (0.60) TDP1ADRA2AADRA2BADRA2CP4HTM
SCHEMBL20254512 0.74 SMN1; SMN2 (0.41) VNN1TDP1PDE10AGABRA1TLR2
SCHEMBL3232177 0.74 IRAK4 (0.42) VNN1TDP1PDE10ATLR2TLR1
SCHEMBL23880060 0.73 SCN9A (0.46) PDE10APLA2G1BATG4BSMN1; SMN2L3MBTL3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10975088-B2 Imidazo[2,1-f][1,2,4]triazine compounds as pi3k-y inhibitors INCYTE CORPORATION (US) 2021-04-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10975088-B2 Imidazo[2,1-f][1,2,4]triazine compounds as pi3k-y inhibitors PIK3R5, PIK3CD, PIK3CA VNN1 4760/4885TDP1 383/4885ADRA2A 1731/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback